Call for Abstract
Submission Deadline
November 12, 2025, Noon (JST)
It was extended until noon on November 26th.
Type of Presentation
- Primary Session
- Oral Session
- Poster Session
Category
| 1 | Thoracic and Thoracoabdominal Aorta | 4 | Lower Extremity Occlusive Disease (Femoral / Popliteal Arteries) |
|---|---|---|---|
| 1-1 Type A Acute Aortic Dissection | 5 | Lower Extremity Occlusive Disease (Below-Knee / Foot Arteries) | |
| 1-2 Type A Chronic Aortic Dissection | 6 | Acute Arterial Occlusion | |
| 1-3 Type B Acute Aortic Dissection | 7 | Peripheral Artery Aneurysm | |
| 1-4 Type B Chronic Aortic Dissection | 8 | Peripheral Artery Diseases (Others, including Upper Extremities) | |
| 1-5 Ruptured Thoracic Aortic Aneurysm | 9 | Vascular Injury | |
| 1-6 Thoracic Aortic Aneurysm (Root / Ascending Aorta) | 10 | Vascular Access | |
| 1-7 Thoracic Aortic Aneurysm (Arch) | 11 | Carotid Artery Disease | |
| 1-8 Thoracic Aortic Aneurysm (Descending Aorta) | 12 | Varicose Veins | |
| 1-9 Thoracoabdominal Aortic Aneurysm | 13 | Deep Vein Thrombosis (DVT) | |
| 1-10 Infected Thoracic Aortic Aneurysm (including Esophageal and Bronchial Fistulae) | 14 | Pulmonary Embolism (Acute / Chronic) | |
| 1-11 Thoracic and Thoracoabdominal Aortic Aneurysms (Others) | 15 | Other Venous Disorders | |
| 2 | Abdominal Aorta and Iliac Arteries | 16 | Lymphatic Disorders |
| 2-1 Juxtarenal and Suprarenal Abdominal Aortic Aneurysm (below the celiac artery) | 17 | Vascular Regeneration | |
| 2-2 Infrarenal Abdominal Aortic Aneurysm | 18 | Perioperative Management | |
| 2-3 Infected Abdominal Aortic Aneurysm (including Gastrointestinal Fistulae) | 19 | Diagnostic Imaging | |
| 2-4 Iliac Artery Aneurysm | 20 | Basic and Translational Research | |
| 2-5 Occlusive Disease of the Abdominal Aorta and Iliac Arteries | 21 | Nursing | |
| 2-6 Other Abdominal Aortic and Iliac Artery Diseases | 22 | Allied Health Professionals | |
| 3 | Visceral Artery (Aneurysm / Occlusive Disease) | 23 | Others |
- The abstracts submitted to the Primary Session may not be accepted for Primary Session but be accepted for Oral Session or Poster Session.
If you do not wish to present in Oral Session nor Poster Session, please notify that in the file of basic information.
Requested theme for Primary Session
| A | All fields |
|---|---|
| A-1 Gender differences in aortic/vascular diseases. | |
| A-2 Why is the number of FEMALE vascular surgeons small in Japan? | |
| A-3 The characteristics of perinatal aortic/vascular diseases. | |
| A-4 Alteration of the surgical indication for aortic/vascular diseases in patients who contemplate pregnancy. | |
| A-5 Alteration of the surgical indication in accordance with the patient’s age. | |
| A-6 Cutting edge of aortic/vascular surgery: AI, imaging modality, robot, etc. | |
| A-7 Traumatic and iatrogenic vascular injury. | |
| B | Thoracic and Abdominal Aorta |
| B-1 Technical issues in aortic surgeries for patients under 20 years-old. | |
| C | Thoracic Aorta |
| C-1 Surgical options for aortic root in the era of TAVI | |
| C-2 Reconsideration about ascending aortic aneurysm: Early intervention? Partial arch replacement? | |
| C-3 Type A acute aortic dissection: surgical strategies for root involvement | |
| C-4 Type A acute aortic dissection: Comparison of entry resection and extent of replacement (HAR, PAR, TAR) | |
| C-5 Type A acute aortic dissection: Surgical outcomes in patients with coma due to malperfusion | |
| C-6 Type A acute aortic dissection: Surgical strategies in elderly and high-risk patients | |
| C-7 Type A acute aortic dissection: Revisiting surgical indication for type A intramural hematoma | |
| C-8 Type A acute aortic dissection: Surgical decision for retrograde extension from the entry in the arch to descending aorta | |
| C-9 FET: Device selection and best practice for optimal outcomes | |
| C-10 FET: Mechanisms and prevention of spinal cord injury | |
| C-11 FET: Pathogenesis and countermeasures for distal SINE | |
| C-12 FET: Options for graft infection | |
| C-13 Preemptive TAR with FET for type B aortic dissection | |
| C-14 How to prevent stroke during arch TEVAR: Routine prophylactic strategy | |
| C-15 How to prevent stroke during arch TEVAR: Management of shaggy aorta | |
| C-16 Outcomes of branched and fenestrated TEVAR for aortic arch lesion | |
| C-17 Thoracoabdominal TEVAR: Outcomes of off-the-shelf device and physician-modified endograft | |
| C-18 Preemptive TEVAR for high-risk uncomplicated type B aortic dissection: What defines high risk? What does “preemptive” mean? | |
| C-19 Can stentgraft (TEVAR, FET) play a role in the management of hereditary aortic diseases? | |
| C-20 Tackling shaggy aorta in the descending thoracic aorta: Technical tips in open repair and TEVAR (Video) | |
| C-21 Lessons from “DEVASTATING” spinal cord injury after descending and thoracoabdominal aortic replacement: Segmental artery reconstruction - Where, When, and How? | |
| C-22 Lifetime management of extensive aortic aneurysms from arch to descending / thoracoabdominal aorta | |
| C-23 “Finish early and go home!”: Tips for streamlined TAR | |
| D | Abdominal Aorta |
| D-1 Type II endoleak after EVAR: Should we prevent? Perspective from long-term results | |
| D-2 Type II endoleak after EVAR: Indication for preemptive embolization | |
| D-3 Type II endoleak after EVAR: Timing and technique of preemptive embolization | |
| D-4 Appropriate procedure for AAA from cost-effectiveness in the OR and during follow-up | |
| D-5 Does CKD affect surgical strategy for AAA? | |
| D-6 Inheritance of skills in graft replacement for AAA: Why it still matters? | |
| D-7 Ruptured AAA: What is the best practice? | |
| D-8 EVAR for ruptured AAA with short necks | |
| D-9 Mid- to long-term result of EVAR: Is reintervention failure? Success? or New Normal? | |
| D-10 Mid- to long-term result of EVAR: Impact of hostile neck. | |
| D-11 Mid- to long-term result of EVAR: Evidence-based selection of stentgraft | |
| D-12 Mid- to long-term result of EVAR: Open conversion - When, Why, and How (plication vs. replacement)? | |
| D-13 Infection of abdominal aorta (native, graft, stentgraft): Surgical outcomes and prophylactic measures | |
| D-14 AAA screening initiatives | |
| E | Peripheral Artery and Vein |
| E-1 Change in revascularization strategy in patients with impaired renal function after RCT (BASIL2 and BEST-CLI) | |
| E-2 Strategy for acute limb ischemia: Role of mechanical aspiration thrombectomy | |
| E-3 The role of DCB in vascular surgery: Evolution of indications and strategies | |
| E-4 Toward the better long-term prognosis of PAD: Technique of femoral endarterectomy | |
| E-5 Toward the better long-term prognosis of PAD: Conversion to bypass surgery after failed EVT (timing, collaboration with interventionists, etc.) | |
| E-6 Toward the better long-term prognosis of PAD: Indication of hybrid therapy | |
| E-7 Toward the better long-term prognosis of PAD: In patients with collagen diseases | |
| E-8 Toward the better long-term prognosis of PAD: In patients with diabetes (including choice of diabetic drug) | |
| E-9 Toward the better long-term prognosis of PAD: Strategies of drug intervention after revascularization (DAPT, DOAC, etc.) | |
| E-10 Tibial revascularization: Pros and cons of bypass using artificial graft | |
| E-11 Tibial revascularization: Is claudication an indication? | |
| E-12 Tibial revascularization: Has endovascular therapy achieved dramatic progress? | |
| E-13 How to rescue the desert foot? | |
| E-14 Strategies for early healing of necrosis and ulcers after revascularization: Current status and future of multidisciplinary approach | |
| E-15 Treatment of visceral artery aneurysms: Based on the new Guidelines (SVS, JSIR) | |
| E-16 Perspective on long-term outcomes of DVT: Clinical features in Japan | |
| E-17 Perspective on long-term outcomes of DVT: Impact of treatment and thrombophilia | |
| E-18 Endovascular treatment of venous diseases: Current status and future in varicose veins (thermal and glue ablation), thrombectomy, and stenting | |
| E-19 Vascular access creation for the senescent patients | |
| E-20 Approach for high-flow shunts? (Including pros and cons of therapeutic indication) | |
| E-21 Role of medical staff in the treatment of peripheral vascular disease |
Abstract Guidelines
Please submit both Abstract in Slide Format and Visual Abstract as PDF files.
- The Abstract in Slide Format will be used for peer review and the Visual Abstract will be published online in the program book.
- Please be sure to use the designated slide templates. The Abstract in Slide Format should consist of 6 slides and the Visual Abstract should be summarized in 1 slide.
| Title | Limited to 30 words |
|---|---|
| Abstract in Slide Format (for peer review) | 6 slides |
| Visual Abstract (for program book) | 1 slide |
| Author and Co-authors Details | Maximum of 15 authors |
| Affiliation Details | Maximum of 10 affiliations |
Abstract in Slide Format and Visual Abstract Guidelines
- Please be sure to use the designated slide templates. The Abstract in Slide Format should consist of 6 slides and the Visual Abstract should be summarized in 1 slide.
- In the PPT template, just click inside the box and start typing.
(Please ignore the Japanese words “マスターテキストの書式設定” in the box in PPT templates.) - Composition of the Abstract in Slide Format:
Slide 1: Title & Background
Slide 2: Aim & Patients
Slide 3: Method
Slide 4: Result 1
Slide 5: Result 2
Slide 6: Discussion & Conclusion - For case report, you may modify the contents of slides 2 to 5 as appropriate to fit your presentation.
- Figures and tables may be included but videos are NOT allowed.
- Affiliations and authors’ names should NOT be included in either the Abstract in Slide Format or the Visual Abstract.
- Please use the Meiryo or Arial font (minimum 24-point size is recommended). There are no restrictions on color or text style (e.g., bold, etc.).
- You may adjust the frame sizes in both templates. When changing the frame sizes in the Visual Abstract, please make sure to reposition the headings (“Key question,” “Key findings,” and “Take-home message”) accordingly.
- The maximum size of the file sent in PDF format is as follows:
Abstract in Slide Format: up to 10 MB
Visual Abstract: up to 5 MB - Templates can be downloaded from the buttons below.
- Please create your Visual Abstract (1 slide) by selecting either “With Figures/Tables” or “Without Figures/Tables.”
Disclosure of Conflict of Interest (COI)
All first authors are required to declare whether they have any conflicts of interest during the period from three years prior to the abstract submission until the time of the presentation, regardless of whether such conflicts exist.
In addition, the COI status must be disclosed on the presentation day.
Acceptance/Rejection of the Abstract
The congress organizer will decide whether to accept or reject the abstract.
The acceptance will be notified by March, along with the presentation style (oral or poster). Please note that the congress organizer will make the final allocation of the accepted abstracts.
Abstract Submission
Please submit the following three files to the Congress Secretariat via email (jsvs54@m.congre.co.jp) with the heading
"JSVS54: Abstract submission from [your name].".
- Abstract in Slide Format (PDF file)
- Visual Abstract (PDF file)
- Word file containing the basic information of your abstract (use the template below)